Innate Pharma

Board/Management Information • Apr 27, 2009

INNATE PHARMA APPOINTS MARCEL ROZENCWEIG, MD, AS SENIOR VICE PRESIDENT, CLINICAL AND REGULATORY STRATEGY

Marseilles, France, April 27, 2009

Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) announces today the strengthening of its management team with the appointment of Marcel Rozencweig, MD, as Senior Vice President in charge of clinical and regulatory strategy.

Dr. Rozencweig is recognized as a world leading expert and opinion leader in medical oncology and anti-cancer drug development. He built and led the clinical research group at Bristol-Myers Squibb ("BMS") that developed all the NCEs brought by BMS to the market from 1983 to 2001 in the area of cancer (including carboplatin and paclitaxel).

Under his leadership, a total of 17 marketing applications (NDAs or sNDAs1 ) were successfully filed by BMS in the area of cancer, HIV and infectious diseases.

Before joining the industry, Dr. Rozencweig pursued an academic career and currently serves as an Adjunct Associate Professor of Medicine at New York University, NY. He created and chaired a number of European groups (EORTC) devoted to multinational drug-oriented and disease-oriented trials (e.g., Early Clinical Trials Group).

Dr. Rozencweig is a medical doctor, graduated from the Université Libre de Bruxelles, in Belgium. Working part-time for Innate Pharma, he will be based in the US.

"We are very pleased to welcome Dr. Rozencweig in Innate Pharma's team. His extensive experience in the development of cancer drugs, and his US perspective well complement the existing expertise within the company" said Hervé Brailly, Innate Pharma's CEO. He added: "His knowledge of the market and key opinion leaders will help us position our drugs and choose the optimal development path for registration in a complex and rapidly evolving environment".

"Joining Innate Pharma is a very exciting opportunity: the Company has a unique portfolio of first-in-class drug candidates and contributing to their development will be a very stimulating challenge for me" said Dr. Rozencweig.

¹ New Drug Application and supplemental New Drug Application

About Innate Pharma

Innate Pharma S.A. (the "Company") is a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, it was initially listed on NYSE-Euronext in Paris in 2006.

The Company has a significant expertise in bringing novel targets to the clinical proof-ofconcept trials of drug candidates. It currently has seven proprietary drug-candidates (two of which in clinical trials) and two programs out-licensed to Novo Nordisk A/S.

Based in Marseilles, France, Innate Pharma had 89 employees as at December 31, 2008.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Innate Pharma to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

Press and Analyst Contacts:

Laure-Hélène Mercier, Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mob: +33 (0)6 64 18 99 59 lmercier@innate-pharma.fr caroline@alizerp.com

Innate Pharma Alize Public Relations

Caroline Carmagnol Phone: +33 (0)1 41 22 07 31